OBJECTIVE: Studies of Caucasian populations have shown conflicting results concerning the association between a promoter polymorphism -169T>C of the Fc receptor-like 3 (FCRL3) gene and rheumatoid arthritis (RA). It is unknown whether FCRL3 is associated with autoantibody status and disease severity. We investigated associations between FCRL3 -169T>C and autoantibody status and joint damage in patients with RA. METHODS: A total of 652 Norwegian patients with RA from 2 cohorts and 981 Norwegian controls, previously genotyped for FCRL3 -169T>C (rs7528684), were studied. Data on anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) were available. The EURIDISS cohort (disease duration ≤ 4 yrs at baseline) was followed longitudinally, with assessment of radiographic hand damage at baseline and after 10 years (n = 117) according to the van der Heijde-modified Sharp score. RESULTS: We found significant associations with ACPA-positive RA for both the C allele (OR 1.28, 95% CI 1.08-1.52, p = 0.004) and the C/C genotype (OR 1.57, 95% CI 1.18-2.10, p = 0.002). Similar associations were seen with RF-positive RA. No association was found with ACPA-negative or RF-negative RA. The C/C genotype was found to be associated with 10-year radiographic progression in multivariate linear and logistic regression analyses, after adjustment for ACPA, erythrocyte sedimentation rate, age, and sex. CONCLUSION: The promoter polymorphism of FCRL3 was associated with autoantibody-positive RA. Despite the low number of patients, the C/C genotype of the FCRL3 polymorphism consistently and independently predicted radiographic progression. These findings suggest that FCRL3 is involved in both disease susceptibility and progression.
OBJECTIVE: Studies of Caucasian populations have shown conflicting results concerning the association between a promoter polymorphism -169T>C of the Fc receptor-like 3 (FCRL3) gene and rheumatoid arthritis (RA). It is unknown whether FCRL3 is associated with autoantibody status and disease severity. We investigated associations between FCRL3 -169T>C and autoantibody status and joint damage in patients with RA. METHODS: A total of 652 Norwegian patients with RA from 2 cohorts and 981 Norwegian controls, previously genotyped for FCRL3 -169T>C (rs7528684), were studied. Data on anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) were available. The EURIDISS cohort (disease duration ≤ 4 yrs at baseline) was followed longitudinally, with assessment of radiographic hand damage at baseline and after 10 years (n = 117) according to the van der Heijde-modified Sharp score. RESULTS: We found significant associations with ACPA-positive RA for both the C allele (OR 1.28, 95% CI 1.08-1.52, p = 0.004) and the C/C genotype (OR 1.57, 95% CI 1.18-2.10, p = 0.002). Similar associations were seen with RF-positive RA. No association was found with ACPA-negative or RF-negative RA. The C/C genotype was found to be associated with 10-year radiographic progression in multivariate linear and logistic regression analyses, after adjustment for ACPA, erythrocyte sedimentation rate, age, and sex. CONCLUSION: The promoter polymorphism of FCRL3 was associated with autoantibody-positive RA. Despite the low number of patients, the C/C genotype of the FCRL3 polymorphism consistently and independently predicted radiographic progression. These findings suggest that FCRL3 is involved in both disease susceptibility and progression.
Authors: F J Li; W J Won; E J Becker; J L Easlick; E M Tabengwa; R Li; M Shakhmatov; K Honjo; P D Burrows; R S Davis Journal: Curr Top Microbiol Immunol Date: 2014 Impact factor: 4.291
Authors: J F Mendoza Rincón; A K Rodríguez Elias; J M Fragoso; G Vargas Alarcón; K Maldonado Murillo; M L Rivas Jiménez; R E Barbosa Cobos; S Jimenez Morales; G Lugo Zamudio; C Tovilla Zárate; J Ramírez Bello Journal: Rheumatol Int Date: 2015-09-08 Impact factor: 2.631
Authors: Maria I Danila; Vincent Albert Laufer; Richard J Reynolds; Qi Yan; Nianjun Liu; Peter K Gregersen; Annette Lee; Marlena Kern; Carl D Langefeld; Donna K Arnett; S Louis Bridges Journal: Mol Med Date: 2017-06-29 Impact factor: 6.354
Authors: Caroline A Brorsson; Suna Onengut; Wei-Min Chen; Janet Wenzlau; Liping Yu; Peter Baker; Alistair J K Williams; Polly J Bingley; John C Hutton; George S Eisenbarth; Patrick Concannon; Stephen S Rich; Flemming Pociot Journal: Diabetes Date: 2015-03-31 Impact factor: 9.461
Authors: Hanna W van Steenbergen; Luis Rodríguez-Rodríguez; Ewa Berglin; Alexandra Zhernakova; Rachel Knevel; Jose Ivorra-Cortés; Tom W J Huizinga; Benjamin Fernández-Gutiérrez; Peter K Gregersen; Solbritt Rantapää-Dahlqvist; Annette H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2015-01-08 Impact factor: 5.156
Authors: José Inácio Salles; Lucas Rafael Lopes; Maria Eugenia Leite Duarte; Dylan Morrissey; Marilena Bezerra Martins; Daniel Escorsim Machado; João Antonio Matheus Guimarães; Jamila Alessandra Perini Journal: BMC Med Genet Date: 2018-07-18 Impact factor: 2.103